Surfolase capsule (100mg)
DrugSurfolase capsule one capsule twice one days fasting administration
NCT Number: NCT02395913
Acebrophylline is metabolized by being separated into Ambroxol and 7-theophylline when orally administered as a salt composed of an acid-base as a compound that was synthesized by and chloride (salifying) the ambroxol to 7-theophylline. Acebrophylline is selectively applied to the bronchial or lung tissue and inhibit the activity of phospholipase bronchoalveolar shows the expectorant action to raise the surface activity of the alveolar, leukotrienes (LTs) and by suppressing the production of prostaglandins (PGs), showed potent anti-inflammatory activity, bronchial was celebrated by reducing the bronchial hyperreactivity to normal state is allowed to recuperate or extended.
It was developed to improve compliance improve pharmaceutically Surfolase capsule(Acebrophylline 100mg) that intake twice daily 100mg to Surfolase CR(Acebrophylline 200mg) that intake once daily 200mg
Looking for future studies?
Notify Me20 year–55 year
Male
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
*Body mass index (kg/m2) = weight(kg)/height(m)2
Exclusion criteria
Surfolase capsule one capsule twice one days fasting administration
one tablet once one days fasting administration.
one tablet once one days fasting administration.
one tablet once one days fasting administration.
Time frame: blood serum sampling
Time frame: blood serum sampling
Time frame: blood serum sampling
Time frame: blood serum sampling
Time frame: blood serum sampling
Hyundai Pharmaceutical Co., LTD.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06105255
Healthy Male
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT05849311
Healthy Male
Beijing, Beijing Municipality, China
View Trial DetailsNCT06194500
Healthy Male
Holbeck, Leeds, United Kingdom
View Trial DetailsNCT04135898
Healthy Male
Bengbu, Anhui, China
View Trial Details